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Chronic pain exists in over 50 million American adults, 
and it can have signifi cant eff ects on an individual’s quality 
of life. Chronic pain is often inadequately treated with 
narcotic painkillers such as opioids. The long-term usage 
of opioids leads to side eff ects like overdose, tolerance, 
and dependence, which decreases the number of eff ective 
treatments available for chronic pain. A better treatment 
alternative would be non-narcotic analgesics that target the 
local transmission of pain (nociception).
Nociception arising from exogenous (environmental) 
and endogenous (internal) irritants is mediated by the 
activation of the Transient Receptor Potential, subfamily 
A1 (TRPA1) channel through calcium infl ux in sensory 
neurons. Although the TRPA1 channel is an analgesic target 
for chronic pain, there are no inhibitors for it that have 
been approved by the Food and Drug Administration. The 
TRPA1 channel is present in both humans and zebrafi sh. 
In zebrafi sh, this channel can be activated by chemical 
irritants (agonists), which would result in an increase in 
swimming behavior (hyperlocomotion). I hypothesized that 
this hyperlocomotion can be used to screen novel anti-
nociceptive drugs.
In my study, I utilized a TRPA1 agonist, ASP7663, to induce 
hyperlocomotion in 5 days-post-fertilization (dpf) zebrafi sh 
larvae, as mentioned in Ganzen, Ko, and colleagues’ 2019 
article in Scientifi c Reports, “A Critical Evaluation of 
TRPA1-Mediated Locomotor Behavior in Zebrafi sh as a 
Screening Tool for Novel Anti-Nociceptive Drug Discovery.” 
Therefore, the TRPA1-mediated hyperlocomotion modeled 
chronic neuropathic pain in humans. Chemicals that could 
block this hyperlocomotion would potentially treat chronic 
pain. To determine the feasibility of my idea, I pre-treated 
5-dpf zebrafi sh larvae with HC030031, a known TRPA1 
antagonist, before challenging them with the ASP7663 
agonist. This pre-treatment blocked the ASP7663-induced 
hyperlocomotion. My results suggest that ASP7663-induced 
hyperlocomotion in 5-dpf zebrafi sh larvae is an eff ective 
in vivo model for screening drugs that act like HC030031. 
Identifying such compounds can lead to non-narcotic 
treatment options for chronic pain.
Research advisors Yuk Fai Leung and Logan Ganzen 
write: “Emre joined this project because of a Collaborative 
Research Grant from the Purdue Institute for Integrative 
Neuroscience. His work has contributed to our 
understanding of how TRPA1 modulates neuropathic 
pain and has resulted in the development of a zebrafi sh 
behavioral assay that can be used to identify novel non-
opiate painkillers.”
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